OpGen Inc OPGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OPGN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.40–0.50
- 52-Week Range
- $0.17–3.84
- Bid/Ask
- $0.40 / $0.45
- Market Cap
- $4.84 Mil
- Volume/Avg
- 1.1 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 100
- Website
- https://www.opgen.com
Valuation
|
Metric
|
OPGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.51 |
Price/Sales | 0.74 |
Price/Cash Flow | — |
Price/Earnings
OPGN
Financial Strength
|
Metric
|
OPGN
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.28 |
Interest Coverage | −10.24 |
Quick Ratio
OPGN
Profitability
|
Metric
|
OPGN
|
|---|---|
Return on Assets (Normalized) | −81.65% |
Return on Equity (Normalized) | −255.45% |
Return on Invested Capital (Normalized) | −83.52% |
Return on Assets
OPGN
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Zmybnvn | Rzzrmc | $186.1 Bil | |
SYK
| Stryker Corp | Ynnkrrhlqv | Jqgl | $128.9 Bil | |
MDT
| Medtronic PLC | Xtqtqgl | Zlxlyq | $107.4 Bil | |
BSX
| Boston Scientific Corp | Vwcxdgwv | Czkht | $106.6 Bil | |
EW
| Edwards Lifesciences Corp | Zqdkxwwvv | Fylbgt | $51.8 Bil | |
DXCM
| DexCom Inc | Yjtclzxsb | Phzg | $49.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Zffwpfxg | Svcc | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Hkqqcbx | Swjgtw | $24.8 Bil | |
ALGN
| Align Technology Inc | Mnpnmfnv | Xjsjd | $22.9 Bil | |
PODD
| Insulet Corp | Nnrrjsscy | Jwhypd | $11.9 Bil |